Head to Head Comparison: Genenta Science (NASDAQ:GNTA) versus X4 Pharmaceuticals (NASDAQ:XFOR)

X4 Pharmaceuticals (NASDAQ:XFOR) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for X4 Pharmaceuticals and Genenta Science, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	0	1	2	0	2.67
Genenta Science	0	0	1	0	3.00

X4 Pharmaceuticals presently has a consensus target price of $3.67, indicating a potential upside of 559.24%. Genenta Science has a consensus target price of $25.00, indicating a potential upside of 439.96%. Given X4 Pharmaceuticals’ higher probable upside, equities research analysts clearly believe X4 Pharmaceuticals is more favorable than Genenta Science.

Valuation and Earnings

This table compares X4 Pharmaceuticals and Genenta Science”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$563,000.00	166.46	-$101.17 million	$0.08	6.95
Genenta Science	N/A	N/A	-$12.60 million	N/A	N/A

Genenta Science has lower revenue, but higher earnings than X4 Pharmaceuticals.

Profitability

This table compares X4 Pharmaceuticals and Genenta Science’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	N/A	-163.17%	-54.32%
Genenta Science	N/A	N/A	N/A

Institutional and Insider Ownership

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 1.6% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

X4 Pharmaceuticals has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Summary

Genenta Science beats X4 Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.